Salarius shares surge 18.32% intraday after announcing name change to Decoy Therapeutics and AI-powered peptide conjugate drug development for antiviral therapies.

Salarius surged 18.32% in intraday trading, with the company announcing a name change to Decoy Therapeutics and a stock ticker change to DCOY, reflecting its focus on developing novel peptide conjugate therapies using an AI-powered platform. The company's antiviral projects targeting coronaviruses and multi-virus threats have attracted attention from global health organizations like BARDA, and it unveiled a 2026 capital-efficient plan to advance clinical trials, expand its R&D pipeline, and seek partnerships.